ABT and EXAS Related Headlines
Go Back- Exact Sciences shareholders approve $105 per share Abbott acquisition
- Exact Sciences Stockholders Approve Acquisition by Abbott
- Exact Sciences stock jumps after Abbott confirms acquisition
- Abbott bets on cancer screening with $23 billion Exact Sciences deal
- Abbott to acquire Exact Sciences for $21 billion in cash deal
- Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments
- BTIG Reiterates Exact Sciences (EXAS) at Buy, 'tie up between ABT and EXAS makes sense'
- Wolfe Research Reiterates Peerperform Rating on Abbott Labs (ABT)
- Exact Sciences shares soar on report Abbott is nearing deal for the company
- Exact Sciences (EXAS) resumes trading, up 28%
- Abbott reportedly nearing deal for Exact Sciences
- Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade
ABT and EXAS Related Press Releases
Go Back- Exact Sciences Stockholders Approve Acquisition by Abbott
- Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments
